Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase-1-first in Man Study in Patients With CALR-mutant Myeloproliferative Neoplasms by Vaccinating With CALR Exon 9 Mutant Peptide

NCT03566446 is registered in ClinicalTrials.gov with Inge Marie Svane as lead sponsor.

NCT NCT03566446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03566446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase-1-first in Man Study in Patients With CALR-mutant Myeloproliferative Neoplasms by Vaccinating With CALR Exon 9 Mutant Peptide
Lead sponsor
Inge Marie Svane
Phase
Phase 1
Overall status
Completed
Start date
June 20, 2018
Completion date
April 30, 2021
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia, myelofibrosis, myeloproliferative neoplasm, unclassifiable